Question for BD or other member with medical expertise:  If apabetalone is approved for use for CVD/CKD in the US by the FDA or for Fabry disease in Canada by HC, will it be available for off-label use in the respective country for other orphan diseases?  Specifically, for an inflammatory disease characterized by up-regulation of many of the pathways that are down-regulated by apabetalone (Il-6, Th1, NF-kB, dendritic cells).  The disease in which I have a particular interest is pulmonary sarcoidosis, but these are common pathways upregulated in many inflammatory diseases that don’t have such a clear (i.e. simple) genetic basis as Fabry.  TIA